REVIEW
Tumour necrosis factor: a cytokine with multiple biological activities G. Semenzato Istituto di Medicina Clinica dell' Universita' di Padova, Clinica Medica 1, Via Giustiniani 2, Padova, Italy. Recently accumulated data provided evidence that cytokines modulate and/or mediate many essential biological processes, in particular those concerned with cell growth and differentiation. These molecules are also mandatory for the regulation of numerous inflammatory and physiological states by displaying a broad range of biological properties. The term biological response modifier that has been applied to the substances belonging to this group extensively encompasses the wide spectrum of activities covered by these molecules. A single cytokine may have multiple effects both in vivo and in vitro, with these properties often overlapping each other and the final result being the sum of the actions of different factors. One of these molecules with pleiomorphic functions is tumour necrosis factor (TNF).
The name assigned to TNF is descriptive of the historical activity of this cytokine and nowadays does not reflect the true spectrum of its biological activity. Lymphotoxin was initially discovered as a cytotoxic factor produced by T cells (Granger & Williams, 1968) and then the term TNF was introduced to describe a serum protein produced after bacterial infections which is capable of causing haemorrhagic necrosis of animal tumours (Carswell et al., 1975) . It is also named cachectin because this molecule was originally isolated during a series of studies aimed at addressing the problem of cachexia in chronic disease states. Two proteins have been characterized and are available as recombinant DNA derived proteins. They are referred to as TNF (or TNF-alpha) , which is predominantly derived from macrophages, and lymphotoxin (or TNF-beta) which is a product of activated lymphocytes.
In the late nineteenth century Coley (1893) observed that patients with streptococcal infection could have partial remission of concurrent malignancies. Although other European investigators noted a link between bacterial infections and cancer remission before Coley, this is the first observation related to the description of TNF. It has been subsequently demonstrated that the bacterial lipopolysaccaride (LPS) was able to trigger the production of a serum factor leading to tumour necrosis without causing shock and widespread tissue injury (Shear, 1944) . Further investigation showed that LPS elicits the production of a host protein capable of inducing the haemorrhagic necrosis of tumours (O'Malley et al., 1962) . The molecule was characterised in the mid 1970s (Carswell et al., 1975) and the material has been eventually sequenced and cloned in the mid 1980s (Pennica et al., 1984) .
TNF and lymphotoxin represent two important mediators in immunity and inflammation. They have a wide range of effects, including modulation of properties of vascular endothelium, induction of other cytokines, induction of antiviral activity, stimulation of bone resorption, angiogenesis and fibroblast growth. Following a brief description of the general properties of TNF, I will analyse the basic functions of this cytokine, notably: (1) its role in tumour cell cytotoxicity and/or growth; (2) its immuno-modulatory activity; and (3) its role in inflammatory responses.
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General properties of TNF
The production of TNF is not unique to a particular cell type. In fact, although the major source of this cytokine is macrophages (Beutler & Cerami, 1987; Aggarwel et al., 1985) , the molecule can also be released by other cell types. These include monocytes stimulated by gamma interferon (Beutler & Cerami, 1987) , T lymphocytes and T cell lines following stimulation with phorbol esters and anti-CD3 antibodies in different combinations (Granger & Williams, 1968; Cutri et al., 1987; Scheurich et al., 1987; Sung et al., 1988a; Turner et al., 1987) , B lymphocytes (Williamson et al., 1983; Sung et al., 1988b) , large granular lymphocytes (Ostensen et al., 1987; Peters et al., 1986) and mast cells (Young et al., 1987) .
The challenge with LPS appears to be the classical inducing agent for the release of TNF (Nedwin et al., 1985b) . Other stimulators acting in vivo include BCG, Corynebacterium parvum, Brucella abortus and interferon gamma (Nedwin et al., 1985b; Old, 1985; Clark, 1982) . As far as the regulation of the production of TNF in vitro is concerned, many stimuli cause cells to release TNF, including the binding of immunecomplexes and phagocytosis by mononuclear phagocytes, interferon gamma, interleukin-2 (IL-2), CSF-1, endotoxin, phorbol esters and viruses (Warren & Ralph, 1986; Strieter et al., 1989b; Beutler & Cerami, 1987 , 1988 . Prostaglandins have demonstrated a suppressive effect on the release of macrophage-derived TNF production (Kunkel et al., 1986 and glucocorticoids have been proved to suppress the transcription of TNF (Remick et al., 1989) . Peripheral blood monocytes and macrophages from different tissues exhibit both a different ability to express and release TNF after in vitro challenge and a different responsiveness to immunomodulators (Martinet et al., 1989; Strieter et al., 1989a) . A differential regulation of TNF-alpha in human alveolar macrophages and peripheral blood monocytes has been documented (Strieter et al., 1989b) . In fact, prostaglandins and corticosteroids serve as potent regulators of LPSinduced TNF from peripheral blood monocytes, while alveolar macrophages are relatively refractory to these suppressive immunomodulating agents (Strieter et al., 1989b) .
The genes for both TNF-alpha and TNF-beta are separated by about I kb of DNA on chromosome 6 within the major histocompatibility complex (Nedwin et al., 1985a; Spies et al., 1986) . The expression of TNF mRNA encodes a precursor of 233 amino acids that is processed to a mature non-glycosylated protein of 17,300 Da containing a single disulphide linkage (Wang et al., 1985) . Recent evidence has been provided favouring the suggestion that TNF-alpha may exist in dimeric or trimeric forms, each subunit of which consisting of an anti-parallel beta-sandwich (Smith & Baglioni, 1987; Jones et al., 1989) . The main chain fold of a TNF subunit shows a remarkable similarity to the 'jelly-roll' struc- Kull et al., 1985) . However, there is no correlation between the number of receptors and cell susceptibility, the cytolytic effect of TNF being dependent on the affinity of specific receptors (Kull et al., 1985; Tsujimoto et al., 1986; Lehemann et al., 1986) . For instance, polymorphonuclear leukocytes possess as much TNF receptors as tumour cell lines susceptible to cytolysis but they are not lysed (Larrick et al., 1987; Tsujimoto et al., 1986; Ruggiero et al., 1987 Kull et al., 1985) . Despite the fact that TNF and IL-1 are cytokines with multiple overlapping activities, TNF does not compete with the IL-1 binding to its receptors (Matsushima et al., 1986 Sugarman et al., 1985; Wang et al., 1985; Tsujimoto et al., 1985) . This variability has been proved to be independent of the number or affinity of TNF receptors, suggesting that a defect in the signal transduction mechanisms leading to the cytotoxic response might take place in unsensitive cells (Shepard & Lewis, 1988) . Free radical generation during the TNF dependent conversion of arachidonic acid to prostaglandins and intracellular release of lysosomal enzymes have been thought to represent the crucial mechanisms accounting for the efficacy of killing capacity (Ruddle, 1987 (Sugarman et al., 1985) . Interestingly, the TNF resistance might be associated with the production of TNF by the resistant cells (Rubin et al., 1986; Spriggs et al., 1987) . It has also been suggested that the transforming growth factors which are produced by different tumour cell lines may protect the tumour cell from destruction by TNF-alpha in vivo (Shepard & Lewis, 1988 (Palladino et al., 1987.) TNF has demonstrated a selective toxicity for leukaemic cells in myeloid leukaemias (Prince et al., 1987 (Leibovich et al., 1987) and to alter the endothelial cell responsiveness (Gamble et al., 1985; Broudy et al., 1987) . In addition, TNF stimulates human vascular endothelial cells to release neutrophil chemotactic factors and to promote the transendothelial neutrophil influx (Moser et al., 1988; Strieter et al., 1988) . It is worth mentioning that other cytokines, particularly IL-1 and INF-o, ,, and y, play an important role in regulating the endothelial responsiveness (Pober et al., 1986; Moser et al., 1988) . Furthermore, TNF increases the expression of class I major histocompatibility complex (MHC) antigens on the vascular endothelium surface (Gamble et al., 1985; Pohlman et al., 1986) . It also increases the production of procoagulants and downregulates the production of thrombomodulin, thus converting vascular endothelium to a procoagulant surface (Stern & Nawaroth, 1986; Bevilacqua et al., 1986) . In fact, thrombomodulin binds to serum proteins S and C to promote local anti-coagulation. This finding, in association with the capacity of TNF to induce inflammatory cell adherence to vessel walls (Nawroth & Stern, 1986; Taylor et al., 1987) , represents an additional factor contributing to a coagulant state with cessation of blood flow and then leading to tissue necrosis.
TNF induces the trapping of neutrophils in localised areas, thus initiating the inflammatory response. In fact, TNF has chemotactic activity that may serve to recruit phagocytic cells from the blood compartment to amplify resistance against noxious agents (Ming et al., 1987) . During an inflammatory reaction, TNF allows neutrophils to respond more efficiently to an invasive agent by increasing their property to phagocytose (Klebanoff et al., 1986) and by activating the superoxide anion production (Larrick et al., 1987) . Once the immune process has been initiated, TNF induces an oxidative burst, degranulation and increased phagocytic activity (Shalaby et al., 1985; Klebanoff et al., 1986) . TNF induces fever initially by increasing prostaglandin E2 synthesis in the hypothalamus and subsequently by triggering the production of IL-1 (Dinarello et al., 1986; Nawroth et al., 1987) . Other factors produced in response to the TNF include platelet-derived growth factor (Hajjar et al., 1987) , platelet-activating factor (Camussi et al., 1987) , prostacyclin (Kawakami et al., 1986) , osteoclasts activating factor (Dewhirst et al., 1985; Bertolini et al., 1986) , and haematopoietic growth factors, including G-CSF and GM-CSF (Broudy et al., 1987; Munker et al., 1986; Trinchieri et al., 1986; Zucali et al., 1988) .
TNF has also been implicated in the remodelling of connective tissue through an action on fibroblasts. In fact, TNF induces fibroblasts to grow and to produce IL-1 , colony stimulating factors (Zucali et al., 1987) , interferon beta-2 (Van Damme et al., 1987) and glycosaminoglycans (Elias et al., 1988) . TNF has been found to be capable of stimulating collagenase and PGE2 production by isolated synovial cells and dermal fibroblasts (Dayer et al., 1985) .
The evidence that mice passively immunised against the hormone are protected against the lethal effect of lypopolysaccaride suggested a primary role of TNF as a mediator of endotoxic shock (Beutler et al., 1985c) . When TNF became available in the recombinant form, and thus in preparations free of contaminating endotoxin, it was possible to demonstrate that TNF itself is able to induce the shock and the tissue injury usually associated with endotoxaemia (Tracey et al., 1985) .
Rats infused with recombinant TNF presented with diarrhoea, piloerection, haemoconcentration, shock, metabolic acidosis and hyperglycaemia followed by hypoglycaemia. Leucostasis, oedema, ischaemic and haemorrhagic lesions have been documented in different organs, including the lung, kidney, adrenal tissue, pancreas and gastrointestinal tract. Furthermore, it has been subsequently demonstrated that non-human primates can be protected against the lethal effects of endotoxin injection by pre-treatment with anti-TNF antibody (Tracey et al., 1987) . TNF has also been demonstrated to contribute to the pathogenesis of septic acute lung injury by producing increased pulmonary permeability and oedema (Stephens et al., 1988) .
The observation that trypanosome-infected rabbits develop an hypertriglyceridaemia associated with suppression of the enzyme lipoprotein lipase (Rouzer et al., 1980) led to the discovery that a murine macrophage mediator, released under the action of LPS or other invasive stimuli, was able to suppress the lipoprotein lipase expression in the fatty tissues of mice and in cultured adipocytes (Kawakami & Cerami, 1981; Kawakami et al., 1987) . This factor was called cachectin and subsequent evaluations revealed that the sequence of cachectin and TNF were indistinguishable (Beutler et al., 1985a) . As a matter of fact, in experimental models it has been demonstrated that nude mice injected with cells constitutionally secreting TNF develop anorexia, weight loss and anaemia (Oliff et al., 1987) .
The immunomodulatory activity TNF has been demonstrated to display a series of speciesspecific effects on different cell types and functions. With regard to the monocyte/macrophage lineage, TNF provides important mechanisms to augment the effector activities of these cells at inflammatory foci. In particular, TNF enhances the cytotoxicity of macrophages (Philip et al., 1986) , induces the synthesis of interleukin-l (Bachwich et al., 1986a) and the expression of Fc receptors (Hoffman & Weinberg, 1987) , and of Ia antigens (Chang & Lee, 1986) . TNF also enhances the production of hydrogen peroxide (Hoffman & Weinberg, 1987) , the synthesis of increased levels of platelet activating factor and prostaglandin E2 (Bachwich et al., 1986a; Camussi et al., 1987).
The action of TNF on lymphocytes is displayed after the initial stimulation of T cells because resting T lymphocytes appear to lack the TNF receptors (Kull et al., 1985) . TNF can stimulate T lymphocytes in a dose-dependent manner (Zucali et al., 1987) and it also modulates the proliferation and differentiation of B lymphocytes (Jelinek & Lipskey, 1987; Kashiwa et al., 1987; Kehrl et al., 1987) . TNF enhances the IL-2R expression on a lymphoblastic null-cell leukaemic line in a fashion similar to that of IL-1 (Lee et al., 1987) . High concentrations of TNF induce T lymphocytes to release interferon gamma and TNF provides a synergistic effect with IL-2 in the generation of LAK cells (Owen-Schaub et al., 1988; Chouaib et al., 1988; Yang et al., 1989) .
TNF induces neutrophils to produce hydrogen peroxide (Shau, 1988) and stimulates human vascular endothelial cells to promote transendothelial neutrophil passage (Moser et al., 1988) .
TNF has been demonstrated to exert an anti-viral effect in vitro, which is mediated through the induction of IFN-beta. In fact, Kohase et al. (1986) and Mestan et al. (1986) showed that recombinant human TNF can produce an anti-viral effect in human diploid fibroblasts. This action of TNF could be abolished in the presence of antiserum specific for IFNbeta. By contrast, Wong & Goeddel (1986) (Koff & Fann, 1986 ), thus attributing a protective role to TNF. TNF-alpha is also able to stimulate the HIV enhancer by activation of the NF-kB transcription factor (Osborn et al., 1989) .
Diseases in which an increase of TNF has been found
As far as experimental models are concerned, TNF has been proved to play an important role in the pathogenesis of cerebral malaria and to represent an effector of the skin and gut lesions of the acute phase of graft versus host disease . Furthermore, a relationship between BCG-induced granulomas and TNF synthesis has been recently reported (Kindler et al., 1989) . In these murine models, the in vivo treatment with an anti-TNF antibody resulted in an almost complete prevention of the above quoted lesions Piguet et al., 1987; Kindler et al., 1989) . These latter findings suggest the hypothesis that the therapeutic possibilities of antibodies or specific antagonists against TNF should be taken into account.
The pleiomorphic effects of TNF on different target cells place this molecule in a pivotal role in modulating acute and chronic disease states. For this reason, the levels of TNF activity have been evaluated in different clinical conditions. No TNF activity was detected in blood cell extracts (Hofsli et al., 1988) but TNF mRNA may be present in vivo (Tovey et al., 1988) .
The role of TNF in the pathogenesis of the cachexia associated with human chronic diseases remains to be determined since TNF cannot be detected in the plasma of cachectic patients. This may be consequent to the low sensitivity of assays presently available (Beutler & Cerami, 1987) . As a matter of fact, a discrepancy has been observed in different biological and enzymatic assays which still need to be solved (Balkwill et al., 1987a; Duncombe et al 1988; Fomsgaard et al., 1988; Munck Petersen & Moller, 1988) .
Increased levels of TNF were associated with poor prognosis in patients with meningococcal infections (Waage et al., 1987; Girardin et al., 1988) . Serum levels of TNF-alpha were positively correlated with the number of risk factors and negatively correlated with blood fibrinogen levels, thus indicating that TNF correlates with the severity of meningococcaemia in children (Girardin et al., 1988 (Scuderi et al., 1986) and autoimmune disorders (Turner et al., 87 (Hahn et al., 1989) , and hairy cell leukaemia (Buck et al., 1988; Lindemann et al., 1989) . In addition, TNF mRNA has been demonstrated on hairy cells stimulated in vitro with TNF (Cordingley et al., 1988a) .
Furthermore, the potential role of TNF as the mediator responsible for the extensive marrow necrosis found in patients with cancer has been suggested (Knupp et al., 1988) .
Increased levels of TNF have been described in the serum of patients with AIDS; this finding has been claimed to be relevant to the pathogenesis of cachexia in this disease (Lahdevirta et al., 1988) . Moreover, TNF-alpha levels were significantly higher in supernatants obtained by monocytes isolated from asymptomatic HIV-infected patients as compared to normal controls (Wright et al., 1988; RouxLombard et al., 1989) . In this regard, conflicting results have been reported in a previous paper by Ammann et al. (1987) . An increase in TNF production by alveolar macrophages recovered from the bronchoalveolar lavage in HIV infected patients has also been demonstrated (Agostini et al., 1989) .
In vivo use of TNF: present status and future directions In rabbits it has been shown that TNF is cleared from the plasma with a half-life of 6-7 min (Beutler et al., 1985b Chapman et al., 1987; Creaven et al., 1987 Creaven et al., , 1989 Sherman et al., 1988) . TNF was administered by the intravenous and subcutaneous rute (Chapman et al., 1987) . The half-line of rTNF administered intravenously was 20 min. Side-effects include fever, chills, rigor, fatigue, diarrhoea, headache, nausea and vomiting, severe hypotension, and fluid retention most likely consequent to a capillary-leakage syndrome similar to that described for IL-2 (Chapman et al., 1987; Creaven et al., 1987; Kimura et al., 1987; Mortiz et al., 1989; Sherman et al., 1988 Kimura et al., 1987) . Transient thrombocytopenia and leukopenia have also been observed (Sherman et al., 1988) .
changes were seen in haemostatic parameters (Chapet al., 1987 (Kist et al., 1988) .
Once the time of injection and doses were been standardised, clinical trials were designed. Large studies are currently underway but, for the time being, no consensus has emerged from preliminary results concerning the clinical efficacy of this lymphokine in the treatment of malignancy, little evidence of TNF anti-tumour activity having been observed in vivo. Although partial remissions were documented in individual patients with colon and pancreatic cancer and B cell lymphomas, only a few clinically significant benefits have been observed (Blick et al., 1987; Creaven et al., 1989; Herrmann, 1989; Moritz et al., 1989; Selby et al., 1987; Sherman et al., 1988) One of the most promising approaches is represented by the use of TNF in association with other interleukins, and in particular with IL-2 since a synergism occurs between TNFalpha and IL-2 in the generation of lymphokine activated killer (LAK) cells (Chouaib et al., 1988; Owen-Schaub et al., 1988; Matossian-Rogers et al., 1989; Yang et al., 1989) . The interaction between IL-2 and TNF on LAK precursors results in a reduction of the IL-2 concentration required for the differentiation of granular lymphocytes into LAK cells.
In fact, the addition of TNF-alpha to peripheral blood lymphocytes stimulated with suboptimal IL-2 concentrations can augment the cytotoxicity to levels observed with 10 times more IL-2 alone and this of course can limit adverse reactions. Furthermore, TNF-alpha either alone or in combination with IL-2 has been demonstrated to increase the generation of specific cytotoxic T lymphocytes (Nakano et al., 1989; Whiteside et al., 1989) . Since the function, but not the toxicity, of these two molecules is synergistic, this piece of information may be clinically adapted to improve the safety and to achieve therapeutic efficacy of immunotherapy trials without appreciable toxicity. In view of these possibilities, it is worth mentioning that once LAK cells are stimulated by tumour targets they become able to secrete TNF (Chong et al., 1989 (Darzynkiewicz et al., 1984) indicates that different schedules of administration need to be explored accurately to determine whether continuous or interrupted availability of TNF is more effective. In addition, the possibility to maximise the accumulation of TNF at the site of tumour growth must be further explored since some remissions have been reported with trials of recombinant TNF after direct injection into the tumour (Taguchi, 1987) .
For the time being, the intercellular network of mechanisms regulating the cytokines circuits in vivo is not sufficiently understood to allow us to predict the anti-tumour effect as well as adverse reactions induced by these immunotherapeutic approaches. The use of lymphokines as pharmacological agents is probably more complicated than initially thought (Paul, 1989) 
